Optical Control of Butyrylcholinesterase (bche) Activity Via Photoswitchable Azobenzene for Potential Treatment of Alzheimer’s Disease

Lei Wang,Ziming Gao,Tianyu Sun,Chen,Jiawei Zhu,Suyu Wang,Yao Chen,Haopeng Sun
DOI: https://doi.org/10.1016/j.bioorg.2024.107845
IF: 5.307
2024-01-01
Bioorganic Chemistry
Abstract:Photopharmacology is an emerging method in medicinal chemistry to achieve light-controlled drug activity. Azobenzene-based photoswitchable ligands have found widespread application as chemical tools in photopharmacological studies. This study pioneers the design and synthesis of a novel series of photoswitchabled butyrylcholinesterase (BChE) inhibitors, achieved by strategically integrating an azo moiety into an N-benzyl benzamide scaffold. Through a meticulous investigation of the structure-activity relationship (SAR), we discovered that the lead compound, Azo-9, , exhibits dynamic cis/trans / trans conformational shifts, dynamically modulating its BChE-binding efficacy. This unique property translates into potential therapeutic benefits, including neuroprotection and cognitive enhancement. Complementary molecular docking simulations underscored the preferential binding of the cis-isomer of Azo-9 to BChE, which was subsequently validated in a glutamate-mediated neuronal injury model. Collectively, Azo-9 emerges as a promising precision tool for Alzheimer's disease (AD) therapy, while also facilitating deeper insights into the disease's underlying mechanisms.
What problem does this paper attempt to address?